You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 10, 2024

Claims for Patent: 9,441,041

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,441,041

Title:	Use of antagonists of the interaction between HIV GP120 and .alpha.4.beta.7 integrin
Abstract:	Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and .alpha.4 integrin, such as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin antagonist, thereby treating the HIV infection. In several examples, the .alpha.4 integrin antagonist is a monoclonal antibody that specifically binds to a .alpha.4, .beta.1 or .beta.7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and .alpha.4 integrin, such as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.
Inventor(s):	Arthos; James (Rockville, MD), Goode; Diana (Bellingham, MA), Cicala; Claudia (Bethesda, MD), Fauci; Anthony S. (Washington, DC)
Assignee:	The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)
Application Number:	14/859,675
Patent Claims:	1. A method for the treatment of a subject infected with human immunodeficiency virus (HIV), comprising: selecting the subject who is infected with HIV; and administering to the subject a therapeutically effective amount of an .alpha.4.beta.7 monoclonal antibody which specifically inhibits binding of a LDV sequence in a gp 120 V2 loop to an .alpha.4.beta.7 integrin heterodimer, thereby treating the subject with HIV. 2. The method of claim 1, wherein the monoclonal antibody is a .beta.7 integrin subunit monoclonal antibody. 3. The method of claim 2, wherein the .beta.7 integrin subunit monoclonal antibody is a humanized form of FIB504 monoclonal antibody, humanized form of FIB27 monoclonal antibody or fragments thereof. 4. The method of claim 1, wherein the HIV is HIV type 1 (HIV-1). 5. The method of claim 1, wherein the HIV is HIV type 2 (HIV-2). 6. The method of claim 1, wherein the antibody is not natalizumab. 7. The method of claim 1, wherein the subject does not have multiple sclerosis or Crohn's disease. 8. The method of claim 1, wherein the subject is a newborn infant. 9. The method of claim 1, wherein the .alpha.4.beta.7 monoclonal antibody is MLN02. 10. The method of claim 1, wherein the .alpha.4.beta.7 monoclonal antibody is administered with an additional agent. 11. The method of claim 10, wherein the additional agent is an anti-viral agent. 12. The method of claim 1, wherein the .alpha.4.beta.7 monoclonal antibody is a human .alpha.4.beta.7 monoclonal antibody.

Details for Patent 9,441,041

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	11/23/2004	⤷ Try a Trial	2026-12-07
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.